Carregant...

EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) improve the clinical outcomes of EGFR-mutant non-small cell lung cancer (NSCLC) patients significantly, however, acquired resistance occurs almost inevitably. The underlying mechanisms of osimertinib resistance and treatment str...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Transl Med
Autors principals: Ma, Lei, Chen, Rui, Wang, Fang, Ma, Li-Li, Yuan, Ming-Ming, Chen, Rong-Rong, Liu, Jiang
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2019
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6545316/
https://ncbi.nlm.nih.gov/pubmed/31205925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2019.04.37
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!